Investors turn to high-yield dividend stocks amid delayed rate cuts and persistent inflation pressures.
High-yield dividend stocks are attracting investor interest as the Federal Reserve delays rate cuts due to stubborn inflation and a resilient labor market. Market volatility may rise, but dependable income streams remain appealing in the current environment.
AbbVie (NYSE: ABBV), a Dividend King with 54 consecutive years of dividend increases, offers a yield exceeding 3%. The company’s portfolio includes 12 blockbuster drugs, seven of which generate over $2 billion in annual sales, with strong growth in autoimmune therapies Skyrizi and Rinvoq.
AbbVie’s pipeline of 60 mid- to late-stage clinical programs and a forward price-to-earnings ratio of 15.8x further bolster its appeal. Double-digit sales growth in key drugs and attractive valuation support its position as a top pick for income-focused investors.